Securities Code: 301520
Securities Abbreviation: Wanbang Pharmaceutical
Announcement Number: 2026-021
Anhui Wanbang Pharmaceutical Technology Co., Ltd.
Announcement on the Acquisition of 75.52% Equity of Anhui Saide Sheng Pharmaceutical Technology Co., Ltd.
The Company and the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.
Special Notice:
-
Anhui Wanbang Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company" or "Wanbang Pharmaceutical") intends to acquire 75.52% of the equity of Anhui Saide Sheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Saide Sheng" or the "Target Company") in cash (hereinafter referred to as the "Transaction"). The Transaction will use the equity valuation issued by a qualified appraisal institution in accordance with the "Securities Law of the People's Republic of China" (hereinafter referred to as the "Securities Law") as a reference for pricing, and the final determined transfer price for the entire equity will be RMB 30,207.76 million. Upon completion of this transaction, Saide Sheng will become a holding subsidiary of the Company and will be included in the consolidated financial statements.
-
The Transaction has been reviewed and approved by the Sixth Meeting of the Third Board of Directors of the Company and does not require submission to the Company's shareholders' meeting for review.
-
The counterparties to the Transaction have no relationship with the Company, its controlling shareholder, actual controller, directors, or senior management. Therefore, the Transaction does not constitute a connected transaction. Furthermore, the Transaction has not reached the standard for major asset restructuring as stipulated in the "Measures for the Administration of Major Asset Restructuring of Listed Companies," and thus does not constitute a major asset restructuring.
-
The Transaction includes performance commitments. The performance obligors undertake that the net profit of the Target Company for the three years from 2026 to 2028 will be no less than RMB 109 million, with the net profit for 2026 being no less than RMB 30 million, the net profit for 2027 being no less than RMB 35.5 million, and the net profit for 2028 being no less than RMB 43.5 million.
-
For details on the risks related to this Transaction, please refer to "VIII. Risk Warning for the Transaction" in this announcement. Investors are kindly advised to pay attention to investment risks.
I. Transaction Overview
(I) Basic Situation of the Transaction
To further improve the Company's business layout in the innovative drug R&D service sector, enrich its business structure, and enhance its comprehensive service capabilities and core competitiveness, the Company signed the "Equity Transfer Agreement" on June 26, 2026, with Wang Jin Hai, Gao Zhi Gang, Hu Gui Feng, Li Zhen, Cao Wen Zhong, Guangzhou Nansha Houyun Consulting Partnership (Limited Partnership), Hefei Lifang Pharmaceutical Co., Ltd., Beijing Shengjing Jiachuang Venture Capital Center (Limited Partnership), Chen Xiaoyu, Zhang Shun, and Wu Kang. The agreement stipulates that the Company will use its own funds or self-raised funds to acquire 75.52% of Saide Sheng's equity for RMB 30,207.76 million. Upon completion of this transaction, Saide Sheng will become a holding subsidiary of the Company and will be included in the consolidated financial statements.
(II) Deliberation Procedures for the Transaction
On June 26, 2026, the Company held the Sixth Meeting of the Third Board of Directors, which reviewed and approved the "Proposal on the Acquisition of 75.52% Equity of Anhui Saide Sheng Pharmaceutical Technology Co., Ltd." This matter had been reviewed and approved by the First Meeting of the Third Strategic Committee of the Company.